89
10. Harvey BS, et al. (2012). Contrasting protective effects of cannabinoids against oxidative stress and amyloid-β evoked neurotoxicity in vitro. Neurotoxicology, 33(1):138-46.
11. Zhang J, et al. (2014). Synaptic and cognitive improvements by inhibition of 2-AG metabolism are through upregulation of microRNA-188-3p in a mouse model of Alzheimer's disease. J Neurosci, 34(45):14919-33.
12. Chen R, et al. (2012). Monoacylglycerol lipase is a therapeutic target for Alzheimer's disease. Cell Rep, 2(5):1329-39
13. Piro JR, et al. (2012). A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer's disease. Cell Rep, 28;1(6):617-23
14. National Institute of Health (NIH), updated October 5, 2017. Safety and Efficacy of Nabilone in Alzheimer's Disease: www.clinicaltrials.gov/ct2/show/NCT02351882.
15. Volicer L, et al. (1997). Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry, 12(9):913-9.
16. Zajac DM, et al. (2015). Nabilone for the Treatment of Dementia-Associated Sexual Disinhibition. Prim Care Companion CNS Disord, 17(1).
17. National Institute of Health (NIH), updated October 27, 2017. Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease: www.clinicaltrials.gov/ct2/show/NCT02792257.
18. in t' Veld BA, et al. (2001) Nonsteroid anti-inflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med, 345(21):1515-21.
19. Moreira FA, and Lutz B. (2008). The endocannabinoid system: emotion, learning and addiction. Addict Biol, 13(2): 196-212.
20. Pascual AC, et al. (2014). Cannabinoid receptor-dependent metabolism of 2-arachidonoylglycerol during aging. Exp Gerontol, 55:134-42.
21. Finseth TA, et al. (2015). Self-reported efficacy of cannabis and other complementary medicine modalities by Parkinson's disease patients in colorado. Evid Based Complement Alternat Med, 2015:874849
22. Venderova K, et al. (2004) Survey on cannabis use in Parkinson's disease: subjective improvement of motor symptoms. Mov Disord, 19(9):1102-6.
23. Lotan I, et al. (2014). Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study. Clin Neuropharmacol, 37(2):41-4.
24. Garcia C, et al. (2011). Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's disease. Br J Pharmacol, 163(7):1495-506.
25. National Institute of Health (NIH), updated April 28, 2017. A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease: www.clinicaltrials.gov/ct2/show/NCT02818777.
26. Chagas MH, et al. (2014). Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial. J Psychopharmacol, 28(11):1088-98.
27. Chagas MH, et al. (2014). Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series. J Clin Pharm Ther, 39(5):564-6.
28. Zuardi AW, et al. (2009). Cannabidiol for the treatment of psychosis in Parkinson’s disease. J Psychopharmacol, 23(8):979-83.
28. Zuardi AW, et al. (2009). Cannabidiol for the treatment of psychosis in Parkinson’s disease. J Psychopharmacol, 23(8):979-83.
17. National Institute of Health (NIH), updated October 27, 2017. Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease: www.clinicaltrials.gov/ct2/show/NCT02792257.
24. Garcia C, et al. (2011). Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's disease. Br J Pharmacol, 163(7):1495-506.
25. National Institute of Health (NIH), updated April 28, 2017. A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease: www.clinicaltrials.gov/ct2/show/NCT02818777.
26. Chagas MH, et al. (2014). Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial. J Psychopharmacol, 28(11):1088-98.
27. Chagas MH, et al. (2014). Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series. J Clin Pharm Ther, 39(5):564-6.
22. Venderova K, et al. (2004) Survey on cannabis use in Parkinson's disease: subjective improvement of motor symptoms. Mov Disord, 19(9):1102-6.
21. Finseth TA, et al. (2015). Self-reported efficacy of cannabis and other complementary medicine modalities by Parkinson's disease patients in colorado. Evid Based Complement Alternat Med, 2015:874849
20. Pascual AC, et al. (2014). Cannabinoid receptor-dependent metabolism of 2-arachidonoylglycerol during aging. Exp Gerontol, 55:134-42.
19. Moreira FA, and Lutz B. (2008). The endocannabinoid system: emotion, learning and addiction. Addict Biol, 13(2): 196-212.
18. in t' Veld BA, et al. (2001) Nonsteroid anti-inflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med, 345(21):1515-21.
23. Lotan I, et al. (2014). Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study. Clin Neuropharmacol, 37(2):41-4.
14. National Institute of Health (NIH), updated October 5, 2017. Safety and Efficacy of Nabilone in Alzheimer's Disease: www.clinicaltrials.gov/ct2/show/NCT02351882.
13. Piro JR, et al. (2012). A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer's disease. Cell Rep, 28;1(6):617-23
11. Zhang J, et al. (2014). Synaptic and cognitive improvements by inhibition of 2-AG metabolism are through upregulation of microRNA-188-3p in a mouse model of Alzheimer's disease. J Neurosci, 34(45):14919-33.
10. Harvey BS, et al. (2012). Contrasting protective effects of cannabinoids against oxidative stress and amyloid-β evoked neurotoxicity in vitro. Neurotoxicology, 33(1):138-46.
12. Chen R, et al. (2012). Monoacylglycerol lipase is a therapeutic target for Alzheimer's disease. Cell Rep, 2(5):1329-39
15. Volicer L, et al. (1997). Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry, 12(9):913-9.
16. Zajac DM, et al. (2015). Nabilone for the Treatment of Dementia-Associated Sexual Disinhibition. Prim Care Companion CNS Disord, 17(1).